EU GMP Annex 4 - Manufacture of Veterinary Medicinal Products

What it says

Manufacture of veterinary medicinal products requires GMP principles adapted for considerations specific to animal health products, including particular attention to cross-contamination prevention for products containing certain highly active or sensitising substances, and specific requirements for medicated premixes intended for incorporation into animal feed.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Veterinary products share the same fundamental GMP quality expectations as human medicinal products but carry specific additional considerations, including feed premix manufacturing controls with no direct equivalent in human pharmaceutical manufacturing.
• Cross-contamination prevention carries particular emphasis for certain veterinary product categories, given the potential for highly potent substances used in some veterinary products and the food chain implications of contamination affecting animals raised for human food consumption.
• The food chain connection distinguishes veterinary GMP from human pharmaceutical GMP in a meaningful way, since contamination or quality failures in veterinary products can have downstream human food safety implications beyond the treated animal's own health.

What inspectors look for

• Whether cross-contamination prevention measures adequately address the specific risk profile of veterinary products, particularly highly active substances and feed premix manufacturing.
• Whether facility and equipment segregation decisions reflect documented risk assessment specific to veterinary product manufacturing considerations.
• Whether quality control testing adequately addresses both animal health and, where relevant, downstream human food safety considerations.

Related regulations